Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug: brivoligide | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 24 Parkinson's papers of 6,086 | 0.58 |
| pathways Reactome | 3 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 5397
Sealed predictions
- EGR1 in dopamine neurons, braak-0.18 (p 0.644) → -0.30 (p 0.430)receipt 5405
Swarm cases
receipt 5405: EGR1 in dopamine neurons, braak
- power
- full sample -0.26 (p 0.306, n 18), 95% CI -0.65 to +0.24. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.17 (p 0.493, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.16 (p 0.515, n 18). could be the mix.
- skeptic
- leave-one-out range -0.36 to -0.15, sign flips 0; without severely affected donors -0.26 (p 0.306, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for EGR1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts